CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
AntibioTx is developing a new class of antibiotics to treat bacterial infections, particularly those resistant to current treatments. The lead candidate, ATx201, is designed for infected atopic dermatitis, offering a topical alternative with a proven safety profile and reduced risk of resistance.
AntibioTx is advancing a chemical class of compounds to be approved and used for the first time to treat bacterial infections.
The class is based on an easy to synthesize chemical scaffold, which enables broad applicability across topical and systemic indications.
AntibioTx discovered that compounds from this class overcome current resistance problems such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci and resistance towards all topical antibiotics.
The c…
UNION THERAPEUTICS AS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
